Brief: Bayer AG Says Phase II Aracog Head-To-Head Trial Met Its Primary Endpoint
30/05/2026 22:27
BRIEF-Bayer AG Says Phase II Aracog Head-To-Head Trial Met Its Primary Endpoint May 30 (Reuters) - Bayer AG BAYGn.DE:
BAYER AG - PHASE II ARACOG (AFT-47) HEAD-TO-HEAD TRIAL MET ITS PRIMARY ENDPOINT
BAYER AG - PATIENTS TREATED WITH NUBEQA(®) (DAROLUTAMIDE) SHOWED A DECLINE IN MAXIMALLY CHANGED COGNITIVE DOMAIN (MCCD) BY 24 WEEKS
Source text: ID:nBwbgnJSQa
Further company coverage: [BAYGn.DE]
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Bayer AG
See all newsBayer takes a giant leap toward investability
Europe Research Roundup: Barratt Redrow, Ferrari, KPN
Explainer: What does Bayer's US Supreme Court win mean for the thousands of Roundup lawsuits?
Bayer shares soar over 18% after U.S. Supreme Court curbs Roundup lawsuits
US Supreme Court scales back Roundup cancer suits in win for Bayer (updated)